Loading...
•
Mar 31, 2023
Aldeyra Q1 2023 Earnings Report
Aldeyra reported financial results for Q1 2023 and provided recent corporate highlights.
Key Takeaways
Aldeyra Therapeutics reported a net loss of $15.6 million, or $0.27 per share, for the first quarter of 2023. The company's cash and cash equivalents totaled $165.0 million as of March 31, 2023.
Top-line results are expected from the Phase 2 clinical trial of ADX-2191 in Retinitis Pigmentosa in Q2 2023.
Top-line results are expected from the Phase 2 clinical trial of ADX-629 in Chronic Cough in Q2 2023.
Top-line results are expected from the Phase 3 INVIGORATE-2 Trial of Reproxalap in Allergic Conjunctivitis in Q2 2023.
Cash and cash equivalents totaled $165.0 million as of March 31, 2023.
Forward Guidance
Aldeyra anticipates multiple regulatory and clinical milestones in the coming quarters.
Positive Outlook
- PDUFA dates for ADX-2191 and reproxalap are planned.
- Top-line results are expected from Phase 2 clinical trials in retinitis pigmentosa.
- Top-line results are expected from Phase 2 clinical trials in chronic cough.
- Top-line results are expected from the Phase 3 INVIGORATE-2 trial in allergic conjunctivitis.
- Existing cash and cash equivalents are expected to fund operating expenses into the second half of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...